相关实验视频
Updated: Jun 20, 2025
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.4K
将ARR与抑制PRA进行比较,作为一次性阿尔多斯特尼症的查测试
Marco Marcelli1, Caixia Bi1, John W Funder2
1Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.M., C.B., M.J.M.).
Hypertension (Dallas, Tex. : 1979)
|July 23, 2024
概括
使用抑制等离子体雷宁活性 (PRA) 检测原发性阿尔多斯特主义的查发现的个体数量明显超过了阿尔多斯特与雷宁比率 (ARR). 这表明抑制的PRA可能是一个更敏感的查工具,用于原发性阿尔多斯特隆症.
科学领域:
- 内分泌学 在内分泌学.
- 临床诊断 临床诊断 临床诊断
- 高血压研究 高血压研究
背景情况:
- 主要的阿尔多斯特性查通常使用来自单次抽血的阿尔多斯特与的比率 (ARR).
- ARR变异性和试验不一致性凸显了这种查方法的潜在局限性.
- 低于1ng/mL/h的抑制血蛋白活性 (PRA) 是作为另一种查方法的建议.
研究的目的:
- 为了比较抑制的PRA与ARR在识别可能的原发性阿尔多斯特主义方面的有效性.
- 在一大群接受初级阿尔多斯特主义检测的患者中评估两种查策略.
主要方法:
- 一项对94,829个配对的血胆固醇活性 (PRA) 和血类固醇度 (PAC) 样本的回顾性分析.
- 查标准的比较:ARR (≥20或≥30) 与抑制的PRA (<1 ng/mL/h).
主要成果:
- 抑制的PRA在45.9%的患者中被发现,明显高于ARR≥20 (20.3%) 或ARR≥30 (13.9%).
- PRA组表现出广泛的阿尔多素水平,表明不同的潜在疾病.
- 与抑制的PRA标准相比,较低的患者百分比满足了ARR标准.
结论:
- 使用抑制的PRA标准检查原发性阿尔多斯特隆症,比基于ARR的方法识别出更多的个体.
- 抑制的PRA可以作为一个更敏感的初始查工具,用于大型临床队列中初级的阿尔多斯特隆症.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
683
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
683
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
632
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
632
01:25Antihypertensive Drugs: Direct Renin Inhibitors
528
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
528
01:31Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:25Assessment of apical radial pulse
736
Apical-Radial (A-R) Pulse Assessment
The A-R pulse assessment involves simultaneous evaluation of the apical and radial pulses. When the apical and radial pulse rates vary, this assessment helps identify a pulse deficit.
Pre-Procedural Preparation
The A-R pulse assessment involves simultaneous evaluation of the apical and radial pulses. When the apical and radial pulse rates vary, this assessment helps identify a pulse deficit.
Pre-Procedural Preparation
736